IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i8d10.1007_s40264-021-01078-8.html
   My bibliography  Save this article

Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities

Author

Listed:
  • Veronique F. Kugener

    (Takeda Pharmaceuticals International Co.)

  • Eric S. Freedland

    (Takeda Pharmaceuticals International Co.)

  • Kenneth I. Maynard

    (Takeda Pharmaceuticals International Co.)

  • Omar Aimer

    (Brunel Canada)

  • Peggy S. Webster

    (GlaxoSmithKline)

  • Maribel Salas

    (University of Pennsylvania)

  • Maxine Gossell-Williams

    (University of The West Indies)

Abstract

This review is intended to present perspectives from the US experience in enhancing pharmacovigilance on current practices and future opportunities. Best practices concepts could be applied worldwide through the presentation of how three pillars of pharmacovigilance: (1) medical and scientific excellence, (2) operational and compliance excellence, and (3) knowledge sharing and experts development in the field could serve as a framework for the establishment of an efficient and successful global pharmacovigilance system.

Suggested Citation

  • Veronique F. Kugener & Eric S. Freedland & Kenneth I. Maynard & Omar Aimer & Peggy S. Webster & Maribel Salas & Maxine Gossell-Williams, 2021. "Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities," Drug Safety, Springer, vol. 44(8), pages 843-852, August.
    • Handle: RePEc:spr:drugsa:v:44:y:2021:i:8:d:10.1007_s40264-021-01078-8
    DOI: 10.1007/s40264-021-01078-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01078-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-021-01078-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:8:d:10.1007_s40264-021-01078-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.